News
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Announces Favorable Topline Results from Phase 1 SAD Study of Oral Ketamir-2, a Next-Generation Non-Scheduled Ketamine Analog
MIRA Pharmaceuticals announces positive Phase 1 results for oral candidate Ketamir-2, showing safe, well-tolerated, predictable absorption, and no CNS side effects -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Reports Positive PTSD Data Demonstrating Ketamir-2 Restores Normalized Behavior in Stressed Animals
MIRA Pharmaceuticals advances Ketamir-2 in clinical trials for neuropathic pain and expands into neuropsychiatric disorders like PTSD, showing promising results in a PTSD model -
-
-
COMMUNIQUÉ DE PRESSE
MIRA Pharmaceuticals Shareholders Approve Acquisition of SKNY Pharmaceuticals, Advancing Next-Generation Oral Therapeutic for Obesity and Smoking Cessation
MIRA Pharmaceuticals to acquire SKNY Pharmaceuticals, enhancing MIRA pipeline with oral drug SKNY-1 for weight loss and nicotine cravings reversal. Shareholders approve merger with $30 million valuation -
-
